Saturday, 26 Sep 2020

Bangla Version

Oxford vaccine trial resumes

No icon Pharmaceuticals

Health Desk-13 September 2020: AstraZeneca, a British pharmaceutical company, is set to resume trials of a possible coronavirus vaccine.

AstraZeneca said: "The trial of the vaccine has been postponed due to safety concerns as a person fell ill in Britain on September 6 during the final stage of testing. The information was then given to the concerned domestic and international authorities. After reviewing them, they gave the green signal to start the test again.

Authorities reviewed information provided by Oxford-AstraZeneca and informed the Medicine Health Regulatory Authority (MHRA) in the UK that it was safe and could be re-tried in the UK.

In that study, which tested the effectiveness of the vaccine by pushing it into the human body, the trial was postponed when a patient showed neurological symptoms related to a rare spinal inflammatory disease called transverse mellitus. According to AstraZeneca, it is not possible to reveal more about the patient.

This is normal in the case of vaccine making. It is a process that is not always fruitful. Despite long-term research, only one incomplete vaccine for dengue fever has been found so far. Since the first trial of the vaccine began in 1986, the number of people receiving HIV (AIDS) is still zero.